Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia

Schizophrenia Research

Volumn 157, Issue 1-3, 2014, Pages 84-89

  Koola, Maju Mathew ^a,b   Buchanan, Robert W ^b   Pillai, Anilkumar ^c   Aitchison, Katherine J ^d   Weinberger, Daniel R ^e   Aaronson, Scott T ^a,b   Dickerson, Faith B ^a,b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

^d UNIVERSITY OF ALBERTA   (Canada)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cognitive impairments; Galantamine; Memantine; Schizophrenia

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; BUNGAROTOXIN RECEPTOR; CHOLINESTERASE INHIBITOR; CLOZAPINE; CYCLOSERINE; DONEPEZIL; GALANTAMINE; GLYCINE; KYNURENINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; RISPERIDONE; RIVASTIGMINE; NOOTROPIC AGENT;

ADJUVANT THERAPY; ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; COGNITION; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; DRUG METABOLISM; HUMAN; IMMUNE RESPONSE; MILD COGNITIVE IMPAIRMENT; MONOTHERAPY; NEGATIVE SYNDROME; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOCIAL COGNITION; VERBAL MEMORY; ANIMAL; COGNITION DISORDERS; DRUG COMBINATION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANIMALS; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; GALANTAMINE; HUMANS; MEMANTINE; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84904107880     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.04.037     Document Type: Review

References (77)

1. Alexander K.S., Pocivavsek A., Wu H.Q., Pershing M.L., Schwarcz R., Bruno J.P. Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience 2013, 238:19-28.
2. Atri A., Shaughnessy L.W., Locascio J.J., Growdon J.H. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 2008, 22(3):209-221.
3. Atri A., Molinuevo J.L., Lemming O., Wirth Y., Pulte I., Wilkinson D. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res. Ther. 2013, 5(1):6.
4. Bressan R.A., Pilowsky L.S. Imaging the glutamatergic system in vivo-relevance to schizophrenia. Eur. J. Nucl. Med. 2000, 27(11):1723-1731.
5. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., Nuechterlein K.H., Laughren T., Levin R., Stover E., Fenton W., Marder S.R. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31(1):5-19.
6. Buchanan R.W., Freedman R., Javitt D.C., Abi-Dargham A., Lieberman J.A. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr. Bull. 2007, 33(5):1120-1130.
7. Buchanan R.W., Javitt D.C., Marder S.R., Schooler N.R., Gold J.M., McMahon R.P., Heresco-Levy U., Carpenter W.T. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am. J. Psychiatry 2007, 164(10):1593-1602.
8. Buchanan R.W., Conley R.R., Dickinson D., Ball M.P., Feldman S., Gold J.M., McMahon R.P. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry 2008, 165(1):82-89.
9. Butterfield D.A., Pocernich C.B. The glutamatergic system and Alzheimer's disease: therapeutic implications. CNS Drugs 2003, 17(9):641-652.
10. Carlsson A., Waters N., Waters S., Carlsson M.L. Network interactions in schizophrenia - therapeutic implications. Brain Res. Brain Res. Rev. 2000, 31(2-3):342-349.
11. Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008, 51(3):347-372.
12. Chew M.L., Mulsant B.H., Pollock B.G., Lehman M.E., Greenspan A., Kirshner M.A., Bies R.R., Kapur S., Gharabawi G. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr. Res. 2006, 88(1-3):63-72.
13. Collier D.A., Li T. The genetics of schizophrenia: glutamate not dopamine?. Eur. J. Pharmacol. 2003, 480(1-3):177-184.
14. Coyle J.T., Tsai G., Goff D.C. Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 2002, 1(2):183-189.
15. de Lucena D., Fernandes B.S., Berk M., Dodd S., Medeiros D.W., Pedrini M., Kunz M., Gomes F.A., Giglio L.F., Lobato M.I., Belmonte-de-Abreu P.S., Gama C.S. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J. Clin. Psychiatry 2009, 70(10):1416-1423.
16. Egerton A., Reid L., McKerchar C.E., Morris B.J., Pratt J.A. Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl) 2005, 179(1):77-84.
17. Erhardt S., Blennow K., Nordin C., Skogh E., Lindstrom L.H., Engberg G. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 2001, 313(1-2):96-98.
18. Fagerlund B., Soholm B., Fink-Jensen A., Lublin H., Glenthoj B.Y. Effects of donepezil adjunctive treatment to ziprasidone on cognitive deficits in schizophrenia: a double-blind, placebo-controlled study. Clin. Neuropharmacol. 2007, 30(1):3-12.
19. Freudenreich O., Herz L., Deckersbach T., Evins A.E., Henderson D.C., Cather C., Goff D.C. Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. Psychopharmacology (Berl) 2005, 181(2):358-363.
20. Friedman J.I., Adler D.N., Howanitz E., Harvey P.D., Brenner G., Temporini H., White L., Parrella M., Davis K.L. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biol. Psychiatry 2002, 51(5):349-357.
21. Furey M.L., Pietrini P., Haxby J.V. Cholinergic enhancement and increased selectivity of perceptual processing during working memory. Science 2000, 290(5500):2315-2319.
22. Geerts H., Grossberg G.T. Pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. J. Clin. Pharmacol. 2006, 46(7 Suppl. 1):8S-16S.
23. Green M.F., Nuechterlein K.H., Kern R.S., Baade L.E., Fenton W.S., Gold J.M., Keefe R.S., Mesholam-Gately R., Seidman L.J., Stover E., Marder S.R. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. Am. J. Psychiatry 2008, 165(2):221-228.
24. Grohmann U., Fallarino F., Puccetti P. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 2003, 24(5):242-248.
25. Grossberg G.T., Edwards K.R., Zhao Q. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. J. Clin. Pharmacol. 2006, 46(7 Suppl. 1):17S-26S.
26. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., Catinari S., Ermilov M. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol. Psychiatry 2005, 57(6):577-585.
27. Hilmas C., Pereira E.F., Alkondon M., Rassoulpour A., Schwarcz R., Albuquerque E.X. The brain metabolite kynurenic acid inhibits α7 nicotinic receptor activity and increases non-α7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 2001, 21(19):7463-7473.
28. Homayoun H., Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J. Neurosci. 2007, 27(43):11496-11500.
29. Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4(11):682-690.
30. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991, 148(10):1301-1308.
31. Keefe R.S., Malhotra A.K., Meltzer H.Y., Kane J.M., Buchanan R.W., Murthy A., Sovel M., Li C., Goldman R. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008, 33(6):1217-1228.
32. Kern R.S., Nuechterlein K.H., Green M.F., Baade L.E., Fenton W.S., Gold J.M., Keefe R.S., Mesholam-Gately R., Mintz J., Seidman L.J., Stover E., Marder S.R. The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. Am. J. Psychiatry 2008, 165(2):214-220.
33. Kern R.S., Gold J.M., Dickinson D., Green M.F., Nuechterlein K.H., Baade L.E., Keefe R.S., Mesholam-Gately R.I., Seidman L.J., Lee C., Sugar C.A., Marder S.R. The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. Schizophr. Res. 2011, 126(1-3):124-131.
34. Kishi T., Iwata N. NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. J. Psychiatr. Res. 2013, 47(9):1143-1149.
35. Koola M.M., Fawcett J.A., Kelly D.L. Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement-based care. J. Nerv. Ment. Dis. 2011, 199(12):989-990.
36. Koola M.M., Varghese S.P., Fawcett J.A. High-dose prazosin for the treatment of post-traumatic stress disorder. Ther. Adv. Psychopharmacol. 2014, 4(1):43-47.
37. Krystal J.H., Karper L.P., Seibyl J.P., Freeman G.K., Delaney R., Bremner J.D., Heninger G.R., Bowers M.B., Charney D.S. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51(3):199-214.
38. Lee M.J., Breese C.R., Strook M.L., Leonard S. The effect of nicotine and haloperidol co-treatment on nicotinic receptor levels in the rat brain. Brain Res. Mol. Brain Res. 2001, 86(1-2):115-124.
39. Lee S.W., Lee J.G., Lee B.J., Kim Y.H. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int. Clin. Psychopharmacol. 2007, 22(2):63-68.
40. Lee J.G., Lee S.W., Lee B.J., Park S.W., Kim G.M., Kim Y.H. Adjunctive memantine therapy for cognitive impairment in chronic schizophrenia: a placebo-controlled pilot study. Psychiatry Invest. 2012, 9(2):166-173.
41. Lieberman J.A., Papadakis K., Csernansky J., Litman R., Volavka J., Jia X.D., Gage A. A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009, 34(5):1322-1329.
42. Lindenmayer J.P., Khan A. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr. Res. 2011, 125(2-3):267-277.
43. Lopes J.P., Tarozzo G., Reggiani A., Piomelli D., Cavalli A. Galantamine potentiates the neuroprotective effect of memantine against NMDA-induced excitotoxicity. Brain Behav. 2013, 3(2):67-74.
44. Maccaferri G., Dingledine R. Control of feedforward dendritic inhibition by NMDA receptor-dependent spike timing in hippocampal interneurons. J. Neurosci. 2002, 22(13):5462-5472.
45. Micuda S., Mundlova L., Anzenbacherova E., Anzenbacher P., Chladek J., Fuksa L., Martinkova J. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions. Eur. J. Clin. Pharmacol. 2004, 60(8):583-589.
46. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J. Neurosci. 1997, 17(8):2921-2927.
47. Morphy R., Rankovic Z. Fragments, network biology and designing multiple ligands. Drug Discov. Today 2007, 12(3-4):156-160.
48. Nordberg A. Neuroreceptor changes in Alzheimer disease. Cerebrovasc. Brain Metab. Rev. 1992, 4(4):303-328.
49. Nuechterlein K.H., Green M.F., Kern R.S., Baade L.E., Barch D.M., Cohen J.D., Essock S., Fenton W.S., Frese F.J., Gold J.M., Goldberg T., Heaton R.K., Keefe R.S., Kraemer H., Mesholam-Gately R., Seidman L.J., Stover E., Weinberger D.R., Young A.S., Zalcman S., Marder S.R. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am. J. Psychiatry 2008, 165(2):203-213.
50. Palmer A.M., Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic?. FASEB J. 1990, 4(10):2745-2752.
51. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., Headley P.M. Novel systemically active antagonists of the glycine site of the N-methyl-d-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 1997, 283(3):1264-1275.
52. Parsons C.G., Stoffler A., Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 2007, 53(6):699-723.
53. Parsons C.G., Danysz W., Dekundy A., Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox. Res. 2013, 24(3):358-369.
54. Peters O., Lorenz D., Fesche A., Schmidtke K., Hull M., Perneczky R., Ruther E., Moller H.J., Jessen F., Maier W., Kornhuber J., Jahn H., Luckhaus C., Gertz H.J., Schroder J., Pantel J., Teipel S., Wellek S., Frolich L., Heuser I. A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J. Nutr. Health Aging 2012, 16(6):544-548.
55. Qazi H., Wijegunaratne H., Savajiyani R., Koola M.M. Naltrexone and Prazosin Combination for Posttraumatic Stress Disorder and Alcohol Use Disorder. The Primary Care Companion for CNS Disorders 2014, (in press).
56. Rogawski M.A., Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 2003, 9(3):275-308.
57. Samochocki M., Hoffle A., Fehrenbacher A., Jostock R., Ludwig J., Christner C., Radina M., Zerlin M., Ullmer C., Pereira E.F., Lubbert H., Albuquerque E.X., Maelicke A. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 2003, 305(3):1024-1036.
58. Santos M.D., Alkondon M., Pereira E.F., Aracava Y., Eisenberg H.M., Maelicke A., Albuquerque E.X. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system. Mol. Pharmacol. 2002, 61(5):1222-1234.
59. Schilstrom B., Ivanov V.B., Wiker C., Svensson T.H. Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors. Neuropsychopharmacology 2007, 32(1):43-53.
60. Schubert M.H., Young K.A., Hicks P.B. Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol. Psychiatry 2006, 60(6):530-533.
61. Sharma U., Morris C., Safranek S. What is the recommended approach to asymptomatic patients who develop a reactive PPD?. J. Fam. Pract. 2006, 55(2):163-165. (discussion 163).
62. Simoni E., Daniele S., Bottegoni G., Pizzirani D., Trincavelli M.L., Goldoni L., Tarozzo G., Reggiani A., Martini C., Piomelli D., Melchiorre C., Rosini M., Cavalli A. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer's disease. J. Med. Chem. 2012, 55(22):9708-9721.
63. Small G., Dubois B. A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch. Curr. Med. Res. Opin. 2007, 23(11):2705-2713.
64. Stone T.W. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol. Rev. 1993, 45(3):309-379.
65. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004, 291(3):317-324.
66. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 2002, 42:165-179.
67. Tugal O., Yazici K.M., Anil Yagcioglu A.E., Gogus A. A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. Int. J. Neuropsychopharmacol. 2004, 7(2):117-123.
68. van Westerloo D., van der Poll T. Acute vagotomy activates the cholinergic anti-inflammatory pathway. Am. J. Physiol. Heart Circ. Physiol. 2005, 288(2):H977-H978. (author reply H978-9).
69. Vinogradov S., Fisher M., Warm H., Holland C., Kirshner M.A., Pollock B.G. The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am. J. Psychiatry 2009, 166(9):1055-1062.
70. Wang E.T., Moyzis R.K. Genetic evidence for ongoing balanced selection at human DNA repair genes ERCC8, FANCC, and RAD51C. Mutat. Res. 2007, 616(1-2):165-174.
71. Wenk G.L., Quack G., Moebius H.J., Danysz W. No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci. 2000, 66(12):1079-1083.
72. Wijegunaratne H., Qazi H., Koola M.M. Chronic and bedtime use of benztropine with antipsychotics: is it necessary?. Schizophr. Res. 2014, 153(1-3):248-249.
73. Wonodi I., Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in schizophrenia. Schizophr. Bull. 2010, 36(2):211-218.
74. Yang C.R., Chen L. Targeting prefrontal cortical dopamine D1 and N-methyl-d-aspartate receptor interactions in schizophrenia treatment. Neuroscientist 2005, 11(5):452-470.
75. Yao C., Raoufinia A., Gold M., Nye J.S., Ramael S., Padmanabhan M., Walschap Y., Verhaeghe T., Zhao Q. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J. Clin. Pharmacol. 2005, 45(5):519-528.
76. Zhao X., Marszalec W., Toth P.T., Huang J., Yeh J.Z., Narahashi T. In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology 2006, 51(7-8):1181-1191.
77. Zimmermann G.R., Lehar J., Keith C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 2007, 12(1-2):34-42.